Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2016

View Archived Issues

SIK2 shows potential to discriminate aggressive from indolent prostate cancer

Clinical results inidcate pro-BNP as a clozapine management biomarker

Centrexion acquires analgesic candidates from Boehringer Ingelheim

Eisai transfers rights to E-7777 to Dr. Reddy's in the U.S., Europe and certain emerging markets

Celimmune initiates phase II study of AMG-714 for refractory celiac disease type II

Positive results from pivotal phase III study of Aplidin for multiple myeloma

Origent Data Sciences and Cytokinetics collaborate on predictive analytics model in ALS

Oncodesign patents RIP-2 kinase inhibitors

Genocea reports 12-month efficacy data from phase II trial of GEN-003 for genital herpes

Bristol-Myers Squibb discloses inhibitors of HIV replication

BCHT initiates clinical trials of influenza vaccine in China

CalAsia Pharmaceuticals develops HSP90/TRAP1 inhibitors

Samumed presents Wnt signaling inhibitors

RedHill reports interim results from phase IIa study of RHB-104 for relapsing-remitting MS

National Chiao Tung University divulges EGFR inhibitors

NIAID grants supports Karyopharm's preclinical evaluation of KPT-350 for SLE

DiaSorin to acquire Focus Diagnostics' molecular and immunoassay product business

Daiichi Sankyo seeks Japanese approval for hydromorphone hydrochloride

Eisai Inc. to transfer AkaRx shares to PBM Capital

Promising topline data from two phase III trials of dupilumab in atopic dermatitis

TFE3 shows potential as a diagnostic marker for solid pseudopapillary neoplasm

Teva and Takeda announce establishment of Teva Takeda Yakuhin in Japan

EphA4 may be useful to predict CCRT response in rectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...